VALNEVA SE revenue breakdown overview

VALNEVA SE revenue for the last year amounted to 159.46 M CHF, the most of which — 159.44 M CHF — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines, the year earlier bringing 142.84 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought VALNEVA SE 45.69 M CHF, and the year before that — 30.63 M CHF.